1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
2.Wei KR, Yu X, Zheng RS, Peng XB, Zhang SW, Ji MF, et al. Incidence and mortality of liver cancer in China, 2010[J]. Chin J Cancer,2014,33(8):388-394.
3.Schwaederle MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, et al. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma[J]. Clin Cancer Res,2017,23(17):5101-5111.
4.Hsu FT, Liu HS, Ali AAA, Tsai PH, Kao YC, Lu CF, et al. Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system[J]. Nanomedicine,2018,14(3):1019-1031.
5.Ooki A, Dinalankara W, Marchionni L, Tsay JJ, Goparaju C, Maleki Z, et al. Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma[J]. Oncogene,2018,37(45):5967-5981.
6.Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma[J]. J Thorac Oncol,2011,6(2):244-285.
7.Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater[J]. Journal of Clinical Oncology,2019,37(7):537-546.
8.Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point[J]. Nature,2017,541(7637):321-330.
9.Ancevski Hunter K, Socinski MA, Villaruz LC. PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer[J]. Molecular Diagnosis & Therapy,2017,22(1):1-10.
10.Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project[J]. Journal of Thoracic Oncology,2017,12(2):208-222.
11.Neuman T, London M, Kania-Almog J, Litvin A, Zohar Y, Fridel L, et al. A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform[J]. J Thorac Oncol,2016,11(11):1863-1868.
12.Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet,2019,393(10183):1819-1830.
13.Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel-Plucinska N, Grzegrzolka J, et al. Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers[J]. Int J Mol Sci,2019,20(4):
14.Yoshiya T, Mimae T, Tsutani Y, Tsubokawa N, Sasada S, Miyata Y, et al. Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma[J]. Ann Thorac Surg,2016,102(5):1668-1673.
15.Xu Y, Zhu C, Qian W, Zheng M. Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma[J]. J Cancer Res Clin Oncol,2017,143(1):181-186.
16.Shimoji M, Shimizu S, Sato K, Suda K, Kobayashi Y, Tomizawa K, et al. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)[J]. Lung Cancer,2016,98(69-75.